It been shown that IL-6 modulates TGF-β1 expression in fibroblasts, however, what role IL-6 plays concerning TGF-βR expression and function in skin is unknown.
| INTRODUCTION
Cytokines and growth factors are known to play critical roles in cellular responses and can ultimately control the function of the cell.
These mediators can serve as molecular signals between cells to communicate changes in the environment or disruptions to homoeostasis, which can occur following an injury. The wound environment is characterized by multiple cellular events within interdependent stages including inflammation, tissue formation and tissue remodelling. Cutaneous homoeostasis is maintained by permanent crosstalk between dermal fibroblasts, epidermal keratinocytes and through the production of cytokines. A paradoxical partnership between cytokines such as interleukin (IL)-6 and transforming growth factor (TGF)-β has long been suspected as a mediator of keratinocyte-fibroblast crosstalk in the wound. [1] Yet, few studies characterizing the mechanism of this partnership exist.
IL-6 is a pleiotropic cytokine that plays a critical role in the inflammatory response as well as in growth and differentiation for numerous cell types. [2] In the skin, IL-6 is produced by dermal and epidermal cells, while other cells such as macrophages, B and T cells and endothelial cells represent secondary sources. [3] Dysregulation of has been implicated in multiple disease states including rheumatoid arthritis, inflammatory bowel disease and psoriasis. [3] Wounds from IL-6-deficient mice demonstrate multiple healing defects, including delayed re-epithelialization, decreased granulation tissue, inhibited neovascularization and greatly increased time to closure, when compared to their wild-type counterparts. [4, 5] While the involvement of IL-6 in the inflammatory process has been well established, much is still unknown about its role in skin.
The TGF-β family consists of TGF-β1-3, bone morphogenic proteins (BMP) and activins. Of the three TGF-β isoforms, TGF-β1 predominates in cutaneous repair exerting pro-and antiproliferative effects in numerous cell types, influencing migration and stimulating the production of extracellular matrix proteins. [6, 7] All isoforms are produced in wounds by macrophages, fibroblast, keratinocytes and platelets. Mouse models deficient for TGF-β1 and its downstream signalling proteins, Smads, demonstrate multiple wound healing deficiencies. [8] The consequences of TGF-β deficiency on re-epithelialization are of particular interest because of the molecule's ability to induce keratinocyte differentiation and subsequent migration, as these are essential processes in re-epithelialization. [9] Indeed, late-stage wounds from TGF-β1 knockout animals demonstrated severely impaired granulation tissue formation, re-epithelialization and collagen deposition;
however, these impairments are accompanied with an unchecked inflammatory response which leads to severe wasting. [10] Thus, it is difficult to discern whether wound healing impairments are a direct consequence of TGF-β1 deficiency or overall physiological effects associated with this animal model.
TGF-β1 exerts its biological activity by binding to a heterotetrameric receptor complex composed of TGF-β type I receptor (TGF-βRI) and TGF-β type II receptor (TGF-βRII) dimers. [7] Ligand binding leads to a formational change in which TGF-βRII phosphorylates and activates TGF-βRI. The activated TGF-βRI recruits R-Smads (Smad2/3 and Smad4) to the receptor where they are phosphorylated and then translocated to the nuclease to modulate transcription of target genes. [11] In addition to inhibitory Smads, such as Smad7, TGF-β1 signalling can be governed by receptor localization within the membrane, specifically within the lipid raft domain vs non-lipid raft. Di Guglielmo et al. [12] previously reported that clathrin internalization into the early endosome antigen-1
(EEA-1)-positive endosome promotes TGF-β signalling, while lipid raft-caveolin internalization pathway (with the help of Smad7) promotes receptor degradation.
Previous studies concerning the relationship between IL-6 and TGF-β have not provided a definitive mechanistic link between the mediators. Concerning its role in dermal-epidermal crosstalk, IL-6 has been shown to induce keratinocyte migration only when cultured in the presence of fibroblasts. [13] This finding seems to indicate that IL-6
facilitates re-epithelialization through its partnership with a soluble effector produced by fibroblasts, such as TGF-β1. This study aims to investigate the relationship of keratinocyte function induced by IL-6
and its association with TGF-β receptor expression and membrane localization. Herein, it was found that IL-6 appears to indirectly modulate keratinocyte activity through functional augmentation of both TGF-β receptors. 
| MATERIALS AND METHODS

| Mice
| Epidermal keratinocyte isolation and culture
IL-6 knockout (KO) epidermis was collected from neonatal mice and isolated as previously described. [13] Neonatal human epidermal keratinocytes (Ker-CT, ATCC CRL-4048 and nHEKs, ThermoFisher, Waltham, MA, USA) were cultured according to manufactures protocol. Cells were treated with IL-6 (overnight for protein expression studies or 1 hour for signalling assays) or in combination with TGF-β1 (30 minutes) or specified otherwise. IL-6 neutralizing antibody (Biolegend, San Diego, CA, USA) was used at 500 ng/mL and incubated overnight followed by treatment. LLL-12 was used at .5 μmol/L for 1 hour.
| Transwell migration assay
Migration of IL-6 KO keratinocytes was assessed via Transwell assay as described [14] and quantified using Image J (NIH).
| Proliferation assays
IL-6 KO keratinocytes were pretreated with IL-6 for 6 hours followed by ±TGF-β1. Bromodeoxyuridine (BrdU) (EMD, Gibbstown, NJ, USA)
was applied immediately following TGF-β1 treatment according to manufacturer's instructions and incubated overnight. Results were obtained via a 96-well plate reader (Molecular Devices, Sunnyvale, CA, USA).
| Semi-quantitative RT-PCR
Total RNA from Ker-CT cultures was prepared, and cDNA was synthesized as described previously. [13] Primers for TGF-BRI and II, Smad7, and 28s rRNA were constructed from GenBank sequences utilizing 
| Immunoprecipitation assay
Ker-CT cultures were cultured and treated as described. Protein G Dynabeads Immunoprecipitation Kit was used according to manufacturer's protocol (ThermoFisher). Western blot was performed as described. [17] Anticaveolin (Cell Signaling, Danvers, MA, USA), anti-TGF-βRII (Cell Signaling) and anti-TGF-βRI (Abcam, Cambridge, MA, USA) were used at the recommended dilution, and IR-labelled secondary antibodies (Licor, Lincoln, NE, USA) were used at 1:10000-1:20 000. Blots were imaged via the Licor Odyssey CLx imaging system (Licor).
| Flow cytometric analysis
Ker-CT cells were cultured and treated with IL-6 and/or TGF-β1.
Single cell suspensions were obtained, and TGF-βRI (Abcam), pSmad-PE (Cell Signaling) and p-Stat3-488 (Cell Signaling) antibodies were used according to recommended dilutions and analysed via the Accuri C6 system.
| Statistical analysis
All experiments were replicated, and representative findings are shown. Statistical significance was determined by two-way analysis of the variance. In all statistical comparisons, a P-value of <.05 was used to indicate a significant difference.
| RESULTS
| IL-6 induces TGF-βRI and TGF-βRII expression in keratinocytes
It was previously shown that intra-dermal injection of IL-6 induces TGF-βRII in IL-6 KO mice. [18] To further confirm these findings, epidermal TGF-βRII expression was determined in mice that specifically over express IL-6 in skin. [16] Immunohistochemistry revealed that epidermal TGF-βRII expression was increased as compared to con- Figure 1C ) and TGF-RII ( Figure 1D ) when compared to control.
| IL-6 alters the function of TGF-β1 in IL-6 KO epidermal cells
TGF-β1 is a known motogen of keratinocytes. [6, 7, 9] To investigate the functional consequences of IL-6 modulation of TGF-βR expression, the migration and proliferation of IL-6 ± TGF-β1-treated KO keratinocytes were assessed. Treatment with 2 ng/mL TGF-β1 alone showed a slight increase in migration; however, this increase was not significant. Migration was significantly increased in a dose-response manner with a maximal response following pretreatment with IL-6 followed by TGF-β1 as determined by Transwell assay (Figure 2A -I vs III and B).
Various studies have shown in respect to skin, TGF-β1 induces proliferation of dermal fibroblasts but suppresses growth of epidermal keratinocytes. [19] Therefore, to assess whether IL-6 affects the antiproliferative activity of TGF-β1, BrdU assays were performed on IL-6
and TGF-β1-treated KO keratinocytes. A significant reduction in BrdU incorporation was seen with 10 ng/mL TGF-β1 alone as compared to control, while pretreatment with IL-6 significantly augmented this response ( Figure 2C ).
| IL-6 modulates TGF-β1-induced signal transduction through Smad2/3 phosphorylation and increases Smad7 expression
TGF-β1-mediated activation of the TGF-β receptor complex initiates signal transduction through the Smad2/3 and 4 pathways. [7] To determine whether IL-6 modulation of TGF-βRI and II expression alters Figure 3B,D, Column 3) . However, following TGF-β1 treatment, a profound increase in the p-Smad high cell population (peak B) was observed accompanied by increased intensity of staining of this population ( Figure 3B,D) . Interestingly, the decrease in peak B cells that was seen in Figure 3A with the combination treatment of IL-6 and TGF-β1 was no longer present when treated with LLL-12, indicating Stat3 involvement ( Figure 3 C vs D, Row 6 ). Multiplex analysis also confirmed that upon IL-6 treatment alone, Smad2/3 phosphorylation was minimal, while TGF-β1 alone showed a marked increase in Smad2/3 phosphorylation ( Figure 3E ). Similar to Figure 3A , pretreatment with IL-6 followed by TGF-β1 treatment, exhibited a significant decrease in Smad2/3 phosphorylation as compared to TGF-β1 treatment alone.
IL-6 KO keratinocytes were also treated in the same manner and multiplex data showed very similar phosphorylation trends (data not shown). Furthermore, research has indicated that expression of the inhibitory Smad7 can also be directly correlated with the transcription from TGF-βR target genes in human keratinocytes and is associated with inhibition of Smad2/3 signalling. [21] Ker-CT cultures were treated with IL-6 and/or TGF-β1, and Smad7 expression was measured via quantitative PCR. Pretreatment with IL-6 and TGF-β1 treatment showed a much more pronounced increase in Smad7 mRNA expression as compared to IL-6 or TGF-β1 treatment alone further corroborating the link between IL-6 and TGF-β1 signalling ( Figure 3F ).
| IL-6 alters localization of TGF-βRI and II within the cell membrane following IL-6 treatment in human epidermal cells
As the multifunctional role of TGF-β1 has been well documented, the spatial organization of the receptor and its signalling components is less clear. Receptor activation not only initiates signal transduction, but also triggers clathrin-or non-clathrin-mediated receptor endocytosis, which serves to further regulate TGF-β1 activity. Therefore, to determine whether IL-6 plays a role in TGF-βR-mediated endocytosis, Ker-CT cells were treated with IL-6 and/or TGF-β1 and immunoprecipitation and immunohistochemistry assays were performed. As shown in Figure 4A ,B, treatment with 5 ng/ml IL-6 induced TGF-βRII immunoprecipitation with caveolin as compared to no IL-6 treatment (Lane 5 vs Lane 6) but decreased the association with TGF-βRI (Lane 1 vs Lane 2). Activation of the receptor with 2 ng/mL TGF-β1 significantly decreased this association of TGF-βRII with caveolin but had no effect on the TGF-βRI interaction. Pretreatment with IL-6 followed by TGF-β1 significantly decreased both receptors interaction with caveolin compared to control (Lane 1 vs Lane 4 and Lane 5 vs Lane 8). Similarly, immunohistochemistry revealed diffuse, punctate staining of TGF-βRII (green) [22] and little to no co-localization with caveolin were also assessed and found that IL-6 treatment did not increase colocalization (results not shown).
| DISCUSSION
Regeneration of dermal and epidermal tissue following cutaneous wounding is a complex process involving the intricate coordination of many cell types in a sequential and predictable pattern. IL-6 and TGF-β are key factors in the normal procession through these events, and both knockout mice display multiple defects in repair. [4, 5] Similar to IL-6, both TGF-βRI and II are minimally distributed in areas such as the epidermis, hair follicles and sebaceous glands, all of which express TGF-β ligands. [6, 23] Following injury, receptor expression increases in the epidermis adjacent to the wound, as does IL-6 expression and tends to persist in older wounds. [24] Herein, it was demonstrated that IL-6 treatment of keratinocytes enhances expression of TGF-βRI and II as compared to controls ( Figure 1A-D) . These results are similar to those found by Zhou, D. et al., which showed IL-6 increased the number of cells expressing TGF-β receptors in the spleen.
[15] The low levels of TGF-β produced by monocultures of keratinocytes and fibroblasts can be increased substantially through co-culturing these two cell types. [1] These findings and the motogenic properties of TGF-β are particularly interesting when considering that IL-6 has been
shown to indirectly induce keratinocyte migration in conjunction with a soluble factor secreted by the dermal fibroblasts. [13] Furthermore, IL-6 treatment has been shown to increase TGF-β1 mRNA expression in a dose-response manner in isolated fibroblasts and dermis. [18] This evidence demonstrates a partnership between the epidermis and the dermis with regard to TGF-β expression and function seemingly driven by IL-6. While IL-6/TGF-β cooperation is well documented in the realm of collagen deposition and myofibroblast contraction, [17, 18, 25, 26] few studies have characterized this partnership with respect to reepithelialization. The present data demonstrate IL-6 pretreatment elicits keratinocyte migration in response to TGF-β1 to a greater extent than TGF-β1 alone (Figure 2A-B) . These results support the notion of IL-6 mediating the keratinocyte-fibroblast interaction exhibited during wound healing through its regulation of the TGF-β ligand and receptor.
While often conflicting, TGF-β has been demonstrated to modulate cell proliferation. [6] Several studies have demonstrated an inhibitory effect on keratinocyte proliferation [19, 27, 28] whereas other have shown that overexpression of TGF-β1 increases the proliferative phenotype of keratinocytes [29, 30] . In our cell system, it was anticipated that following IL-6 treatment, the antiproliferative activity of TGF-β would be It is well established that TGF-β signal transduction is carried out through the intricate and highly regulated Smad2/3 signalling pathway, which is involved in repair by regulating migration, proliferation and differentiation [7, [31] [32] [33] . In Smad3 null mutant mice, inflammatory infiltration into the dermis as well as keratinocyte proliferation is altered during repair. [22] Unfortunately, little is known regarding the role of Smad2 in repair as the null genotype is embryonic lethal. [34] Herein, it is shown that pretreatment with IL-6 and addition of TGF-β1 resulted in a marked increase in function of TGF-βR as evidenced by increased migration ( Figure 2B ). Further, it was found that following treatment, keratinocyte cultures form two distinct populations, an apparent p-Smad low and p-Smad high ( Figure 3A during re-epithelialization [35] while increased Stat3 can induce migration and inhibit differentiation [36, 37] . This may indicate that peaks A and B could be separate populations of differentiated and undifferentiated cells. However, this was not assessed directly herein and further study will be needed to determine this definitively. Treatments indicated as ng/mL of IL-6-TGF-β1: Lane 1 and Lane 5=0-0 ng/mL, Lane 2 and Lane 6=5-0 ng/mL, Lane 3 and Lane 7=0-2 ng/mL, Lane 4 and Lane 8=5-2 ng/mL. (B) nHEKs were cultured in eight-chamber slides and treated with (I) 0 ng/mL and (II) 10 ng/mL IL-6. Slides were stained with anti-TGF-βRII (green) and anticaveolin (red) and detected using Alexa-Fluor 488 or 546-conjugated secondary antibodies, respectively. Stained slides were visualized at 40× objective; photographs are representative of three replicate experiments effects on transcription of TGF-β-induced genes. [38] [39] [40] Herein, it was demonstrated that Smad7 mRNA expression appears to be directly correlated with TGF-β1 treatment in keratinocytes as indicated by a significant increase in mRNA expression ( Figure 3F ). Furthermore, pretreatment with IL-6 enhances TGF-β1-induced Smad7 mRNA expression supporting the observed decrease in TGF-βR signalling (Figure 3) . These results were similar to studies that identified a molecular link by which Smad7 mediates crosstalk with IL-6-mediated Stat3 hyperactivation and attenuation of TGF-βR signalling. [41] It was shown that increased Stat3 activation in mouse embryonic fibroblasts treated with an IL-6/sIL-6r fusion protein resulted in impaired phosphorylation and nuclear translocation of Smad2. [41] Additionally, Stat3 directly interacts with Smad3 and interferes with the Smad3-Smad4 complex [42] and activated Stat3 also induces Smad7 expression to desensitize TGF-βR signalling. [41] Indeed, IL-6 induced Stat3 expression and activation is increased in injured epidermis as compared to uninjured epidermis; [43] therefore, Stat3 activation may be a modulatory link between IL-6R and TGF-βRII function during repair. Inhibition of Stat3 signalling, through the use of the novel small molecule inhibitor LLL-12, further supports this association in Figure 3B , where TGF-β1-induced signalling significantly increased upon inhibition of Stat3.
TGF-β receptors are constitutively internalized via clathrindependent or lipid raft (caveolin-rich)-dependent endocytic pathways [40, 44, 45] upon ligand binding to regulate receptor activity. The balance between the two internalization pathways is critical in modulating receptor activity. Data presented herein show an increased association between caveolin and TGF-βRII following IL-6 treatment but decreased TGF-βRI association with caveolin, although the interaction is still considerably higher than TGF-βRII association. Interestingly, the reciprocal immunoprecipitation found that only TGF-βRI showed association with caveolin and IL-6 and TGF-β1 increased this association (data not shown). Irrelevant IgG antibody was also used as a control, and no bands were indicated confirming the specificity of our pull down (data not shown). This suggests IL-6 may modulate TGF-β activity by trafficking the receptor to the lipid raft portion of the membrane ( Figure 4 ). These data support previous findings that a direct interaction occurs between both TGF-βRI and II, and caveolin [46, 47] .
These interactions have functional consequences as evidenced by a significant decrease in Smad2 phosphorylation upon receptor activation ( Figures 3 and 4) . Interestingly, a previous study in human renal cells found that IL-6 increased compartmentalization of TGF-βRI and II into the non-lipid raft portion of the cell membrane, which further enhances TGF-β signalling. [48] Thus, it might be concluded that in the current model, IL-6-induced compartmentalization of TGF-βR into lipid rafts would decrease signalling, and indeed, this is the case (Figure 3 ).
This would seem paradoxical when considering the apparent increase in TGF-βRI and II expression and function in keratinocytes when pretreated with IL-6 ( Figure 1 and 2) . However, it may be that this apparent IL-6-mediated shift into the lipid raft is a regulatory mechanism initiated to keep the resulting increase in TGF-βR expression and further or persistent signalling in check through increased receptor turnover.
It was recently shown that TGF-βRII was detected in EEA-1-positive compartments and as inflammation progressed (by day 5), the receptor appeared in caveolin-1-positive intracellular structures as well, indicating a potential mechanism to control TGF-βR activity in inflammatory conditions. [47] Perhaps once receptor expression attains a certain threshold or a particular Smad-regulated function is required (such as migration), TGF-βRII is directed into the lipid raft domain ultimately resulting in degradation of the receptor in an attempt to terminate any potential (over) signalling, and this may be represented by peak A in Figure 3 . Interestingly, kinase activation by bFGF and PDGF signalling was suppressed by manipulation of caveolin-1 expression itself, which is likely to influence trafficking of the receptor. [49] Similarly, our studies found that in nHEKs treated with IL-6, total caveolin protein expression increased in a dose-response manner (data not shown). It is also shown that the ratio of TGF-β binding to either TGF-βR can also determine the internalization pathway [11] and IL-6 may modulate the receptor expression and ultimately alter this ratio. It has also been shown in that 10% of IL-6R subunits associate with lipid rafts and treatment with a lipid raft inhibitor disrupted IL-6 signalling further supporting this link.
Herein, it was demonstrated that IL-6 plays a role in keratinocyte migration and proliferation through modulation of TGF-βR expression and function. The current findings, when viewed with previous results, illustrate a model of IL-6 involvement in skin TGF-β function where enhanced TGF-β1 secretion in the dermis [18] and upregulation of TGF-βR in the epidermis may facilitate the differentiation of epidermal keratinocytes to the pro-migratory phenotype observed during re-epithelialization. However, further research into the mechanisms by which IL-6 mediates receptor upregulation and membrane localization is necessary for a more complete understanding of the IL-6/TGF-β interaction in skin and in the dynamic process of wound healing.
